

Seyedmojtaba Seyedmousavi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5360532/publications.pdf>

Version: 2024-02-01

109
papers

24,573
citations

101384

36
h-index

28224

105
g-index

112
all docs

112
docs citations

112
times ranked

39223
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1789-1858.	6.3	8,569
2	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1736-1788.	6.3	4,989
3	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1923-1994.	6.3	3,269
4	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1859-1922.	6.3	2,123
5	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	4.6	970
6	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , the, 2019, 6, e831-e859.	2.1	341
7	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 2091-2138.	6.3	335
8	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 69-89.	5.2	326
9	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	6.5	262
10	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Oncology</i> , The, 2019, 20, 1211-1225.	5.1	199
11	Waterborne <i>Exophiala</i> species causing disease in cold-blooded animals. <i>Persoonia: Molecular Phylogeny and Evolution of Fungi</i> , 2011, 27, 46-72.	1.6	191
12	<i>Aspergillus</i> and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. <i>Medical Mycology</i> , 2015, 53, 765-797.	0.3	172
13	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	13.7	161
14	Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1329-1349.	4.6	144
15	Fungal infections in animals: a patchwork of different situations. <i>Medical Mycology</i> , 2018, 56, S165-S187.	0.3	141
16	Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 37-59.	4.6	104
17	Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 60-79.	4.6	95
18	Black Yeasts and Their Filamentous Relatives: Principles of Pathogenesis and Host Defense. <i>Clinical Microbiology Reviews</i> , 2014, 27, 527-542.	5.7	94

#	ARTICLE	IF	CITATIONS
19	The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside. <i>Drug Resistance Updates</i> , 2014, 17, 37-50.	6.5	89
20	Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 368-375.	1.4	87
21	Phaeohyphomycoses, Emerging Opportunistic Diseases in Animals. <i>Clinical Microbiology Reviews</i> , 2013, 26, 19-35.	5.7	76
22	<i>Exophiala sideris</i> , a novel black yeast isolated from environments polluted with toxic alkyl benzenes and arsenic. <i>Fungal Biology</i> , 2011, 115, 1030-1037.	1.1	72
23	Discrimination of Aspergillosis, Mucormycosis, Fusariosis, and Scedosporiosis in Formalin-Fixed Paraffin-Embedded Tissue Specimens by Use of Multiple Real-Time Quantitative PCR Assays. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2798-2803.	1.8	68
24	Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran. <i>Mycopathologia</i> , 2016, 181, 89-95.	1.3	67
25	Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 931-941.	2.0	65
26	Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 385-393.	1.3	60
27	Pharmacodynamics of Isavuconazole in an <i>Aspergillus fumigatus</i> Mouse Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2855-2866.	1.4	60
28	Azole-Resistant <i>Aspergillus fumigatus</i> , Iran. <i>Emerging Infectious Diseases</i> , 2013, 19, 832-834.	2.0	58
29	Neglected fungal zoonoses: hidden threats to man and animals. <i>Clinical Microbiology and Infection</i> , 2015, 21, 416-425.	2.8	54
30	Epidemiological changes in tinea capitis over the sixty years of economic growth in China. <i>Medical Mycology</i> , 2015, 53, 691-698.	0.3	50
31	Overview of selected virulence attributes in <i>Aspergillus fumigatus</i> , <i>Candida albicans</i> , <i>Cryptococcus neoformans</i> , <i>Trichophyton rubrum</i> , and <i>Exophiala dermatitidis</i> . <i>Fungal Genetics and Biology</i> , 2018, 111, 92-107.	0.9	48
32	Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2299-2304.	1.4	43
33	Systemic Antifungal Agents: Current Status and Projected Future Developments. <i>Methods in Molecular Biology</i> , 2017, 1508, 107-139.	0.4	42
34	Pharmacodynamics and Dose-Response Relationships of Liposomal Amphotericin B against Different Azole-Resistant <i>Aspergillus fumigatus</i> Isolates in a Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1866-1871.	1.4	38
35	Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC). <i>Journal of Clinical Microbiology</i> , 2021, 59, e0178420.	1.8	38
36	Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 9-27.	2.0	37

#	ARTICLE	IF	CITATIONS
37	Efficacy of Olorofim (F901318) against <i>Aspergillus fumigatus</i> , <i>A. nidulans</i> , and <i>A. tanneri</i> in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	37
38	Emergence of fusarioses in a university hospital in Turkey during a 20-year period. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1683-1691.	1.3	36
39	Genotyping and In Vitro Antifungal Susceptibility Testing of <i>Fusarium</i> Isolates from Onychomycosis in India. <i>Mycopathologia</i> , 2016, 181, 497-504.	1.3	36
40	In Vitro Interaction of Voriconazole and Anidulafungin against Triazole-Resistant <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 796-803.	1.4	35
41	Predominance of non- <i>fumigatus</i> <i>Aspergillus</i> species among patients suspected to pulmonary aspergillosis in a tropical and subtropical region of the Middle East. <i>Microbial Pathogenesis</i> , 2018, 116, 296-300.	1.3	35
42	Biofilm Formation and Resistance to Fungicides in Clinically Relevant Members of the Fungal Genus <i>Fusarium</i> . <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 16.	1.5	32
43	Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental <i>Aspergillus flavus</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	31
44	Emerging <i>Aspergillus</i> Species Almost Exclusively Associated With Primary Immunodeficiencies. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy213.	0.4	28
45	Effect of involved <i>Aspergillus</i> species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis. <i>Journal of Medical Microbiology</i> , 2017, 66, 898-904.	0.7	27
46	Antifungal Susceptibility Patterns of Opportunistic Fungi in the Genera <i>Verruconis</i> and <i>Ochroconis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3285-3292.	1.4	26
47	Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR ₃₄ /L98H- and TR ₄₆ /Y121F/T289A-Positive <i>Aspergillus fumigatus</i> Isolates Obtained from Patients in Iran from 2010 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 387-392.	1.4	23
48	Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1487-1494.	1.4	22
49	Topical and systemic antifungals in dermatology practice. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 225-237.	1.3	22
50	Multiple subcutaneous cysts due to <i>Exophiala spinifera</i> in an immunocompetent patient. <i>Medical Mycology</i> , 2012, 50, 207-213.	0.3	20
51	Effects of Low-Level Laser Irradiation on the Pathogenicity of <i>Candida albicans</i> : In Vitro and In Vivo Study. <i>Photomedicine and Laser Surgery</i> , 2014, 32, 322-329.	2.1	20
52	Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2346-2351.	1.4	20
53	Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole. <i>Medical Mycology Case Reports</i> , 2017, 16, 16-19.	0.7	20
54	<i>Aspergillus fumigatus</i> alkaline protease 1 (Alp1/Asp f13) in the airways correlates with asthma severity. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 423-425.e7.	1.5	19

#	ARTICLE	IF	CITATIONS
55	Fungal epidemiology in cystic fibrosis patients with a special focus on <i>Scedosporium</i> species complex. <i>Microbial Pathogenesis</i> , 2019, 129, 168-175.	1.3	19
56	Burden of fungal infections in Iran. <i>Journal of Infection in Developing Countries</i> , 2018, 12, 910-918.	0.5	19
57	Plasma and Epithelial Lining Fluid Pharmacokinetics of Ceftolozane and Tazobactam Alone and in Combination in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3373-3376.	1.4	18
58	Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant <i>Aspergillus flavus</i> Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	18
59	Dermatophytosis due to <i>Microsporum incurvatum</i> : Notification and Identification of a Neglected Pathogenic Species. <i>Mycopathologia</i> , 2016, 181, 107-113.	1.3	17
60	<i>In Vitro</i> Antifungal Susceptibility Profiles of 12 Antifungal Drugs against 55 <i>Trichophyton schoenleinii</i> Isolates from Tinea Capitis Favosa Patients in Iran, Turkey, and China. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17
61	<i>In Vivo</i> Efficacy of Olorofim against Systemic <i>Scedosporiosis</i> and <i>Lomentosporiosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0043421.	1.4	17
62	Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. <i>Current Opinion in Pharmacology</i> , 2011, 11, 486-493.	1.7	16
63	Pharmacodynamics of Anidulafungin against Clinical <i>Aspergillus fumigatus</i> Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 303-308.	1.4	16
64	<i>Aspergillus flavus</i> Keratitis: Experience of a Tertiary Eye Clinic in Turkey. <i>Mycopathologia</i> , 2017, 182, 379-385.	1.3	16
65	In-vitro antifungal susceptibility testing of Itraconazole and Isavuconazole against <i>Aspergillus flavus</i> as an important agent of invasive aspergillosis. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 157-160.	0.8	16
66	Genetic diversity and antifungal susceptibility patterns of <i>Aspergillus nidulans</i> complex obtained from clinical and environmental sources. <i>Mycoses</i> , 2020, 63, 78-88.	1.8	16
67	Discrimination of <i>Aspergillus flavus</i> from <i>Aspergillus oryzae</i> by matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry. <i>Mycoses</i> , 2019, 62, 1182-1188.	1.8	15
68	Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of <i>Talaromyces marneffeii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	15
69	Comparison of the <i>In Vitro</i> Activities of Newer Triazoles and Established Antifungal Agents against <i>Trichophyton rubrum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4312-4314.	1.4	14
70	Time-Kill Kinetics and <i>In Vitro</i> Antifungal Susceptibility of Non- <i>fumigatus</i> <i>Aspergillus</i> Species Isolated from Patients with Ocular Mycoses. <i>Mycopathologia</i> , 2016, 181, 225-233.	1.3	14
71	Exogenous Stimulation of Type I Interferon Protects Mice with Chronic Granulomatous Disease from Aspergillosis through Early Recruitment of Host-Protective Neutrophils into the Lung. <i>MBio</i> , 2018, 9, .	1.8	14
72	Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2964-2967.	1.4	13

#	ARTICLE	IF	CITATIONS
73	Virulence Attributes and Antifungal Susceptibility Profile of Opportunistic Fungi Isolated from Ophthalmic Infections. <i>Mycopathologia</i> , 2016, 181, 653-661.	1.3	13
74	Estimated burden of serious human fungal diseases in Turkey. <i>Mycoses</i> , 2019, 62, 22-31.	1.8	13
75	Antifungal Susceptibility Profile of <i>Candida Albicans</i> Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. <i>Mycopathologia</i> , 2019, 184, 413-422.	1.3	13
76	Molecular epidemiology and antifungal susceptibility profiles of clinical <i>Cryptococcus neoformans</i> / <i>Cryptococcus gattii</i> species complex. <i>Journal of Medical Microbiology</i> , 2020, 69, 72-81.	0.7	13
77	Identification of clinical dermatophyte isolates obtained from Iran by matrix-assisted laser desorption/ionization time-offlight mass spectrometry. <i>Current Medical Mycology</i> , 2019, 5, 22-26.	0.8	13
78	Differentiation of <i>Aspergillus flavus</i> from <i>Aspergillus oryzae</i> Targeting the <i>cyp51A</i> Gene. <i>Pathogens</i> , 2021, 10, 1279.	1.2	13
79	<i>Cryptococcus neoformans</i> Recovered From Olive Trees (<i>Olea europaea</i>) in Turkey Reveal Allopatry With African and South American Lineages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 384.	1.8	12
80	Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	11
81	<i>In vitro</i> antifungal susceptibility of <i>Trichophyton violaceum</i> isolated from tinea capitis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1072-1075.	1.3	10
82	Conventional Morphology Versus PCR Sequencing, rDNA-PCR, and MALDI-TOF-MS for Identification of Clinical <i>Aspergillus</i> Isolates Collected Over a 2-Year Period in a University Hospital at Kayseri, Turkey. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 745-750.	0.9	9
83	Cryptococcosis: Emergence of <i>Cryptococcus gattii</i> in Animals and Zoonotic Potential. , 2018, , 249-287.		9
84	National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1121-1134.	1.0	9
85	Recent Advances in Genome Editing Tools in Medical Mycology Research. <i>Journal of Fungi (Basel)</i> , 2021, 7, 1078-1091.	0.784314	9
86	ATR-FTIR Spectroscopy Highlights the Problem of Distinguishing Between <i>Exophiala dermatitidis</i> and <i>E. phaeomuriformis</i> Using MALDI-TOF MS. <i>Microbial Ecology</i> , 2016, 71, 339-346.	1.4	8
87	MGL_3741 gene contributes to pathogenicity of <i>Malassezia globosa</i> in pityriasis versicolor. <i>Mycoses</i> , 2018, 61, 938-944.	1.8	8
88	Fungal rhino sinusitis in tehran, iran. <i>Iranian Journal of Public Health</i> , 2015, 44, 374-9.	0.3	8
89	Isolation and Characterization of Clinical Triazole Resistance in Iran. <i>Iranian Journal of Public Health</i> , 2018, 47, 994-1000.	0.3	8
90	Infrequent Production of Xanthomegnin by Fungal Strains Recovered from Patients with Ocular Mycoses. <i>Mycopathologia</i> , 2016, 181, 241-246.	1.3	7

#	ARTICLE	IF	CITATIONS
91	Genetic Diversity and Antifungal Susceptibility of <i>Candida parapsilosis</i> Sensu Stricto Isolated from Bloodstream Infections in Turkish Patients. <i>Mycopathologia</i> , 2018, 183, 701-708.	1.3	7
92	Genetic diversity and antifungal susceptibility of <i>Candida albicans</i> isolated from Iranian patients. <i>Medical Mycology</i> , 2019, 57, 127-131.	0.3	7
93	Diagnosis of allergic bronchopulmonary aspergillosis in patients with persistent allergic asthma using three different diagnostic algorithms. <i>Mycoses</i> , 2021, 64, 272-281.	1.8	7
94	A 9-Month-Old Girl from Iran with Extensive Erythematous Plaques Due to <i>Trichophyton simii</i> , a Zoophilic Dermatophyte. <i>Mycopathologia</i> , 2016, 181, 451-455.	1.3	6
95	Antifungal Use in Veterinary Practice and Emergence of Resistance. , 2018, , 359-402.		6
96	<i>In Vivo</i> Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant <i>Aspergillus fumigatus</i> Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	5
97	Azole Resistance in <i>Aspergillus fumigatus</i> : Mechanisms, Route of Resistance Selection, and Clinical Implications. , 2017, , 403-421.		5
98	Clinical and Laboratory Features of Six Cases of <i>Candida</i> and Dermatophyte Folliculitis and a Review of Published Studies. <i>Mycopathologia</i> , 2016, 181, 97-105.	1.3	4
99	Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-Threatening <i>Candida</i> Infections. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1033-1033.	2.5	2
100	Defective calcineurin/NFAT signaling in myeloid cells and susceptibility to aspergillosis in post-transplant patients. <i>Virulence</i> , 2017, 8, 1498-1501.	1.8	2
101	Annotated Genome Sequence of <i>Aspergillus tanneri</i> NIH1004. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.3	2
102	Cutaneous hyalohyphomycosis due to <i>Petriella setifera</i> following traumatic inoculation in an immunocompetent host. <i>Medical Mycology Case Reports</i> , 2021, 32, 56-60.	0.7	2
103	Azole Resistance in <i>Aspergillus fumigatus</i> : Mechanisms, Route of Resistance Selection, and Clinical Implications. , 2015, , 1-17.		2
104	Development of RFLP method for rapid differentiation of <i>Aspergillus flavus</i> and <i>Aspergillus oryzae</i> , two species with high importance in clinical and food microbiology. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101274.	0.7	2
105	Absent <i>in vitro</i> interaction between chloroquine and antifungals against <i>Aspergillus fumigatus</i> . <i>Clinical Microbiology and Infection</i> , 2017, 23, 679-681.	2.8	1
106	<i>Ochroconis globalis</i> infecting Atlantic salmon (<i>Salmo salar</i>), with a review of <i>Ochroconis</i> species in cold-blooded animals. <i>Journal of Fish Diseases</i> , 2019, 42, 947-957.	0.9	1
107	Multicenter Cryptococcal Antigen Screening of HIV-Infected Patients in Iran. <i>Current Microbiology</i> , 2020, 77, 1667-1672.	1.0	1
108	Genotyping and <i>In Vitro</i> Antifungal Susceptibility Profile of <i>Neoscytalidium</i> Species Isolates from Respiratory Tract. <i>Mycopathologia</i> , 2021, 186, 833-845.	1.3	1

#	ARTICLE	IF	CITATIONS
109	Aspergillosis in Humans and Animals. , 2019, , 81-98.		1